NCT03949231View on ClinicalTrials.gov

Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 1, 2029

Study Completion Date

January 2, 2038

Conditions
Liver Cancer
Interventions
DRUG

PD1/PDL1 inhibitor

Infusion of PD1/PDL1 inhibitor through peripheral vein or hepatic artery.

Trial Locations (1)

51260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER